Evolving therapy for Helicobacter pylori infection

Bibliography

• DE FRANCESCO V, ZULLO A, RINALDI V et al.: Relationship between antral lymphocyte density and basal gastrin levels in patients with Helicobacter pylori infection. Dig. Liver Dis. (2000) 32:676–681.
   PubMedGoogle Scholar
• LEUNG WK, SUNG JJ: Review article: intestinal metaplasia and gastric carcinogenesis. Aliment. Pharmacol Ther. (2002) 16:1209–1216.
   PubMed Web of Science ®Google Scholar
• GISBERT JP, KHORRAMI S, CARBALLO F, CALVET X, GENE E, DOMINGUEZ-MUNOZ E: Meta-analysis: Helicobacter pylori eradication therapy versus antisecretory non-eradication therapy for the prevention of recurrent bleeding from peptic ulcer. Aliment. Pharmacol Then. (2004) 19:617–629.
   PubMedGoogle Scholar
• GISBERT JP, PAJARES JM: Review article: Helicobacter pyloriinfection and gastric outlet obstruction - prevalence of the infection and role of antimicrobial treatment. Aliment. Pharmacol Then. (2002) 16:1203–1208.
   PubMedGoogle Scholar
• RINALDI V, ZULLO A: Duodenal stenosis and Helicobacter pylori I Gin. Gastroenterol (1999) 28:83–84.
   Google Scholar
• PARSONNET J, HANSEN S, RODRIGUEZ L et al.: Helicobacter pylori and gastric lymphoma. N Engl. I Med. (1994) 330:1267–1271.
   PubMed Web of Science ®Google Scholar
• BAYERDORFFER E, MORGNER A: Gastric marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type: management of the disease. Dig. Liver Dis. (2000) 32:192–194.
   PubMedGoogle Scholar
• WATANABE T, TADA M, NAGAI H et al.: Helicobacter pylori infection induces gastric cancer in mongolian gerbils. Gastroenterology (1998) 115:642–648.
   PubMed Web of Science ®Google Scholar
• HUANG JQ, SRIDHAR S, CHEN Y, HUNT RH: Meta-analysis of the relationship between Helicobacter pylori seropositivity and gastric cancer. Gastroenterology (1998) 114:1169–1179.
   PubMed Web of Science ®Google Scholar
• NARDONE G: Risk factor of cancer development in Helicobacter pylori gastritis. Dig. Liver Dis. (2000) 32\(Supp1.1):190–192.
   Google Scholar
• UEMURA N, OKAMOTO S, YAMAMOTO S et al.: Helicobacter pylori infection and the development of gastric cancer. N Engl. J. Med. (2001) 345:784–789.
   PubMed Web of Science ®Google Scholar
• INTERNATIONAL AGENCY FOR RESEARCH ON CANCER: Infection with Helicobacter pylori. In: Schistosomes, liver flukes and Helicobacter pylori. IARC, Lyon (1994):177–202.
   Google Scholar
• MOAYYEDI P, DEEKS J, TALLEY NJ, DELANEY B, FORMAN D: An update of the Cochrane systematic review of Helicobacter pylori eradication therapy in nonulcer dyspepsia: resolving the discrepancy between systematic reviews. Am. J. Gastroenterol (2003) 98:2621–2626.
   PubMed Web of Science ®Google Scholar
• ABRAHAM NS, MOAYYEDI P, DANIELS B, VELDHUYZEN VAN SJ: Systematic review: the methodological quality of trials affects estimates of treatment efficacy in functional (non-ulcer) dyspepsia. Aliment. Pharmacol Ther: (2004) 19:631–641.
   PubMed Web of Science ®Google Scholar
• EL-OMAR EM, RABKIN CS, GAMMON MD et at Increased risk of noncardia gastric cancer associated with proinflammatory cytokine gene polymorphisms. Gastroenterology (2003) 124:1193–1201.
   PubMed Web of Science ®Google Scholar
• RICCI C, MENEGATTI M, GATTA L, HOLTON J, MORETTI C, VAIRA D: Association between Helicobacter pylori and disease. In: Helicobacter pylori therapy Holton J, Vaira D, Menegatti M, Miglioli M (Eds.), Mosby-Wolfe, Milan (1998):29–38.
   Google Scholar
• ZULLO A, RINALDI V, HASSAN C, LAURIA V, ATTILI AF: Gastric pathology in cholecystectomy patients: role of Helicobacter pylori and bile reflux. I Clin. Gastroenterol (1998) 27:335–338.
   PubMedGoogle Scholar
• BACKERT S, SCHWARZ T, MIEHLKE S et al.: Functional analysis of the cag pathogenicity island in Helicobacter pylori isolates from patients with gastritis, peptic ulcer, and gastric cancer. Infect. Litman. (2004) 72:1043–1056.
   Google Scholar
• DZIERZANOWSKA-FANGRAT K, CRABTREE JE, ROZYNEK E et al: Helicobacter pylori cagA genotype and density of colonization in relation to gastric inflammation in children. Eur. I Gastroenterol Htpatol. (2002) 14:1303–1307.
   PubMedGoogle Scholar
• ANNIBALE B, CAPURSO G, DELLE GF: The stomach and iron deficiency anaemia: a forgotten link. Dig. Liver Dis. (2003) 35:288–295.
   PubMedGoogle Scholar
• FRANCHINI M, VENERI D. Helicobacter pylori infection and immune thrombocytopenic purpura: an update. Helicobacter (2003) 9:342–346.
   Google Scholar
• DE KOSTER E, DE BRUYNE I, LANGLET P, DELTENRE M: Evidence based medicine and extradigestive manifestations of Helicobacter pylori. Acta Gastroenterol Belg. (2000) 63:388–392.
   PubMedGoogle Scholar
• ZULLO A, HASSAN C, MORINI S: Hepatic encephalopathy and Helicobacter pylori: a critical reappraisal.' Clin. Gastroenterol (2003) 37:164–168.
   Google Scholar
• RICCI V, ZARRILLI R, ROMANO M: Voyage of Helicobacter pyloriin human stomach: odyssey of a bacterium. Dig. Liver Dis. (2002) 34:2–8.
   PubMedGoogle Scholar
• •A review regarding the pathogenic mechanisms involved in H pylori infection.
   Google Scholar
• MORINI S, ZULLO A, HASSAN C, LORENZETTI R, STELLA F, MARTINI MT: Gastric cardia inflammation: role of Helicobacter pylon and gastro-oesophageal reflux disease. Am. J. Gastroenterol (2001) 96:2337–2340.
   PubMed Web of Science ®Google Scholar
• SHEU BS, LIN XZ, YANG HB, CHIEN CH: Cardiac biopsy of stomach may improve the detection of H pylori after dual therapy. Hepatogastroenterol (1999) 46:543–548.
   PubMedGoogle Scholar
• SUTTON P, DOIDGE C: Helkobacter pylori vaccines spiral into the new millenium. Dig. Liver Dis. (2003) 35:675–687.
   PubMedGoogle Scholar
• ••A comprehensive review regarding allaspects of vaccine development.
   Google Scholar
• DE FRANCESCO V, ZULLO A, MARGIOTTA M et al.: Sequential treatment for Helicobacter pyloriinfection does not share the risk factors of triple therapy failure. Aliment. Pharmacol Then. (2004) 19:407–414.
   PubMed Web of Science ®Google Scholar
• GISBERT JP, MARCOS S, GISBERT JL,PAJARES JM: Helicobacter pylori eradication therapy is more effective in peptic ulcer than in non-ulcer dyspepsia. Eur. I Gastroenterol Hepatol (2001) 13:1303–1307.
   PubMed Web of Science ®Google Scholar
• TORACCHIO S, MARZIO L: Primary and secondary antibiotic resistance of Helicobacter pylori strains isolated in central Italy during the years 1998-2002. Dig. Liver Dis. (2003) 35:541–545.
   PubMedGoogle Scholar
• DORE MP, LEANDRO G, REALDI G, SEPULVEDA AR, GRAHAM DY: Effect of pretreatment antibiotic resistance to metronidazole and clarithromycin on outcome of Helicobacter pyloritherapy: a meta-analytical approach. Dig. Dis. Sci. (2000) 45:68–76.
   PubMed Web of Science ®Google Scholar
• MAJEWSKI SH, GOODWIN CS: Restriction endonuclease analysis of the genome of Campylobacter pylori with rapid extraction method: evidence for considerable genomic variation. Infer. Dis. (1988) 157:465–471.
   PubMed Web of Science ®Google Scholar
• ZULLO A, HASSAN C, MORINI S: Helkobacter pyloriinfection: to culture or not to culture? Dig. Liver Dis. (2003) 35:357–361.
   Google Scholar
• LAMBERT JR: Pharmacology of the gastric mucosa: a rational approach to Helicobacter polytherapy. Gastroenterology (1996) 111:521–523.
   PubMed Web of Science ®Google Scholar
• GODDARD AF, JESSA MJ, BARRETT DA et al.: Effect of omeprazole on the distribution on metronidazole, amoxycillin, and clarithromycin in human gastric juice. Gastroenterology (1996) 111:358–367.
   PubMed Web of Science ®Google Scholar
• SCARPIGNATO C: Towards the ideal regimen for Helicobacter pylon eradication: the search continues. Dig. Liver Dis. (2004) 36:234–247.
   Google Scholar
• MATSUO K, HAMAJIMA N, IKEHARA Y et al.: Smoking and polymorphisms of fucosyltransferase gene Le affect success of H pylori eradication with lansoprazole, amoxicillin, and clarithromycin. Epidennol Infect. (2003) 130:227–233.
   PubMedGoogle Scholar
• ZULLO A, RINALDI V, HASSAN C et al.:Clinical and histologic predictors of Helicobacter pylori infection recurrence. Clin. Gastroenterol (2000) 31:38–41.
   Google Scholar
• RUSSO F, BERLOCO P, CUOMO R et al.: Helicobacter pylori strains and histologically-related lesions affect the outcome of triple eradication therapy: a study from southern Italy. Aliment. Pharmacol Ther. (2003) 17:421–428.
   PubMedGoogle Scholar
• O'MORAIN C, DETTMER A, RAMBOW A, VON FRITSCH E, FRASER AG: Double-blind, multicenter, placebo-controlled evaluation of clarithromycin and omeprazole for Helicobacter pylorkassociated duodenal ulcer. Helicobacter (1996) 1:130–137.
   PubMedGoogle Scholar
• DE BOER WA, KUIPERS EJ, KUSTERS JG: Sequential therapy: a new treatment for Helicobacter pylori infection. But is it ready for general use? Dig. Liver Dis. (2004) 36:311–314.
   PubMedGoogle Scholar
• GRAHAM DY, LEW GM, MALATY HM, EVANS DG: Factors influencing the eradication of Helicobacter pylon with triple therapy. Gastroenterology (1992) 102:493–496.
   PubMed Web of Science ®Google Scholar
• MALFERTHEINER p, MEGRAUD F, MORAIN CO et al.: Current concepts in the management of Helkobacter pyloriinfection. The Maastricht 2–2000 Consensus Report. Aliment. Pharmacy] Ther. (2002) 16:167–180.
   Google Scholar
• •Current European guidelines on H pylori management.
   Google Scholar
• LAHEIJ RJ, VAN ROSSUM LG, JANSEN JB, STRAATMAN H, VERBEEK AL: Evaluation of treatment regimens to cure Helicobacter pyloriinfection. A meta-analysis. Aliment. Pharmacol The]: (1999) 13:857–864.
   PubMed Web of Science ®Google Scholar
• JANSSEN MJR, VAN OIJEN AH, VERBEEK AL, JANSEN JB, DE BOERWA: A systematic comparison of triple therapies for treatment of Helicobacter py/oriinfection with proton pump inhibitor/ ranitidine bismuth citrate plus clarithromycin and either amoxycillin or a nitroimidazole. Aliment. Pharmacol Ther. (2001) 15:613–624.
   PubMedGoogle Scholar
• •A comprehensive meta-analysis on standard triple therapy efficacy.
   Google Scholar
• DELLA MONICA P, LAVAGNA A, MASOERO G, LOMBARDO L, CROCELLA L, PERA A: Effectiveness of Helicobacter pylon eradication treatments in a primary care setting in Italy. Aliment. Pharmacol Ther. (2002) 16:1269–1275.
   PubMedGoogle Scholar
• CALVET X, GARCIA N, LOPEZ T, GISBERT JP, GENE E, ROQUE M: A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helkobacter pyloriinfection. Aliment. Pharmacol Ther. (2000) 14:603–608.
   PubMed Web of Science ®Google Scholar
• GENE E, CALVET X, AZAGRA R, GISBERT JP: Triple versus quadruple therapy for treating Helicobacter pylori infection: an updated meta-analysis. Aliment. Pharmacol The]: (2003) 18:543–544.
   PubMed Web of Science ®Google Scholar
• GRAHAM DY, BELSON G, ABUDAYYEDI S, OSATO MS, DORE MP, EL ZIMAITY HM: Twice daily (midday and evening) quadruple therapy for H pylori infection in the United States. Dig. Liver Dis. (2004) 36:384–387.
   PubMedGoogle Scholar
• ZULLO A, HASSAN C, MORINI S: Quadruple therapy as a first-line Helicobacter pyloritreatment: past or future? Dig. Liver Dis. (2004) 36:377–379.
   Google Scholar
• ZULLO A, RINALDI V, WINN S et al: A new highly effective short-term therapy schedule for Helicobacter pylon eradication. Aliment. Pharmacol Ther. (2000) 14:715–718.
   PubMed Web of Science ®Google Scholar
• ZULLO A, VAIRA D, VAKIL N et al: High eradication rates of Helicobacter pylori with a new sequential treatment. Aliment. Pharmacol The]: (2003) 17:719–726.
   PubMed Web of Science ®Google Scholar
• •First large, randomised study showing that a novel sequential therapy is more effective than standard triple therapy.
   Google Scholar
• DE FRANCESCO V, ZULLO A, HASSAN C et al.: The prolongation of triple therapy for Helicobacter pylori does not allow reaching therapeutic outcome of sequential scheme: a prospective, randomised study. Dig. Liver Dis. (2004) 36:322–326.
   PubMedGoogle Scholar
• CAMMAROTA G, CIANCI R, CANNIZZARO O et al: Efficacy of two one-week rabeprazole/levofloxacin-based triple therapies for Helicobacter pylori infection. Aliment. Pharmacol Ther. (2000) 14:1339–1343.
   PubMed Web of Science ®Google Scholar
• ZULLO A, HASSAN C, DE FRANCESCO V et al.: A third-line levofloxacin-based rescue therapy for Helicobacter pylori eradication. Dig. Liver Dis. 2003 35:232–236.
   Google Scholar
• WATANABE Y, AOYAMA N, SHIRASAKA D et al.: Levofloxacin-based triple therapy as a second-line treatment after failure of Helicobacter pylori eradication with standard triple therapy. Dig. Liver Dis. (2003) 35:711–715.
   PubMedGoogle Scholar
• ZULLO A, HASSAN C, LORENZETTI Ret al: Helicobacter pylori eradication: do we have another ace up our sleeve? Dig. Liver Dis. (2001) 33:805–806.
   Google Scholar
• DI MARIO F, ARAGONA G, BO ND, INGEGNOLI A et al.: Use of lactoferrin for Helicobacter pylori eradication. Preliminary results. Clin. Gastroenterol (2003) 36:396–398.
   PubMed Web of Science ®Google Scholar
• DI MARIO F, ARAGONA G, DAL NB et al.: Use of bovine lactoferrin for Helicobacter pylon eradication. Dig. Liver Dis. (2003) 35:706–710.
   PubMedGoogle Scholar
• GUTTNER Y, WINDSOR HM, VIIALA CH, MARSHALL BJ: Human recombinant lactoferrin is ineffective in the treatment of human Helicobacter pylori infection. Aliment. Pharmacol Ther. (2003) 17:125–129.
   PubMed Web of Science ®Google Scholar
• GUTTNER Y, WINDSOR HM, VIIALA CH, DUSCI L, MARSHAL BJ: Nitazoxanide in treatment of Helicobacter pylori. a clinical and in vitrostudy. Antimicrob. Agents Chernother. (2003) 47:3780–3783.
   PubMed Web of Science ®Google Scholar
• GUO CY, WU YB, LIU HL, WU JY et al: Clinical evaluation of four one-week triple therapy regimens in eradicating Helicobacter py/oriinfection. World J. Castroenterol (2004) 10:747–749.
   PubMedGoogle Scholar
• IWAO E, YAMAMOTO K, YOKOYAMA Y et al: Potent antibacterial activity of Y-754, a novel benzimidazole compound with selective action against Heliwbacterpylori I Infect. Chemother. (2004) 10:90–96.
   Google Scholar
• HIGO S, ORI K, TAKEUCHI H et al: A novel evaluation method of gastric mucoadhesive property in vitro and the mucoadhesive mechanism of tetracycline-sucralfate acidic complex for eradication of Helicobacter pylori Pharm. Res. (2004) 21:413–419.
   Google Scholar
• HEEP M, BECK D, BAYERDORFFER E et al.: Rifampin and rifabutin resistance mechanism in Helicobacter pylori Antimicrob. Agents Chemother: (1999) 43:1497–1499.
   PubMed Web of Science ®Google Scholar
• HOLTON J, VAIRA D, MENEGATTI M et al.: The susceptibility of Helicobacter pylorito the rifamycin, rifaxymin. .1. Antimicrob. Chemother: (1995) 35:545–549.
   Google Scholar
• DELL'ANNA A, ARDIZZONE P, FERRIERI A: A randomized openly comparative study between rifaximin suspension versus rifaximin pills for the eradication of Helicobacter pylori Eur: Rev. Med. Pharmacol Sci. (1999) 3:105–110.
   Google Scholar
• DE GIORGIO R, STANGHELLINI V, BARBARA G et al.: Rifaximin and Helicobacter pylori eradication. Lim Rev Med. Pharmacol Sci. (1997) 1:105–110.
   PubMedGoogle Scholar
• PERRI F, FESTA V, CLEMENTE R et al:Rifabutin-based 'rescue therapy' for Helicobacter pyloriinfected patients after failure of standard regimens. Aliment. Pharmacol Then. (2000) 14:311–316.
   PubMed Web of Science ®Google Scholar
• PERRI F, FESTA V, CLEMENTE R et al.: Randomized study of two 'rescue' therapies for Helicobacter pylori-infected patients after failure of standard triple therapies. Am. .1. Castroenterol (2001) 96:58–62.
   Google Scholar
• CANDUCCI F, OJETTI V, OIKA O et al:Rifabutin-based Helicobacter pylori eradication 'rescue therapy'. Aliment. Pharmacol Then. 2002; 15:143 (letter).
   Google Scholar
• CAREANAGUE D, SHUE YK, WOUNOLA MA et al.: Novel structures derived from 2- [[(2-pyridyl)mathyl]thiol-1H-benzimidazole as anti- Helicobacter pylori agents, Part 2. Med. Chem. (2002) 45:4300–4309.
   Google Scholar
• KOBOYASHI I, MURAOKA H, HASEGAWA M et al.: In vitro anti-Helicobacter pylori activity of BAS-118, a new benzamide derivative. Antimicrob. Chemother: (2002) 50:129–132.
   Google Scholar
• KATSURA Y, NSHINO S, INOUE Y et al.: Anti- Helicobacter pylori agents. 5.2-(Substituted guanidino)-4-arylthiazoles and aryloxazole analogues. I Med. Chem. (2002) 45:143–150.
   Google Scholar
• ••In this study, a molecule with the highestin vitro antibacterial activity against H pylori was described.
   Google Scholar
• HASUOKA A, NISHIKIMI Y, NAKAYAMA Y et al.: Synthesis and anti-Helicobacter pylori activity of pyloricidin derivatives II. The combination of amino acid residues in the dipeptidic moiety and its effect on the anti-Helicobacter pylori activity. Antibiot. (2002) 55:499–507.
   Google Scholar
• ••This interesting study showed a very highefficacy of a novel family of natural antibiotics against H pylon both in vitro and in vivo.
   Google Scholar
• YOSHIDA Y, MATSUDA K, SASAKI H et al.: Studies on anti-Helicobacter pylori agents. Part 3: a novel, efficacious cephem derivative, FR193879. Bioorg. Med. Chem. Lett. (2004) 14:2627–2631.
   Google Scholar
• SANCHEZ JEG, SAENZ NG, RINCON MR et al: Susceptibility of Heticobacterpy/ori to mupirocin, oxazolidinones, quinupristin/dalfopristin and new quinolones. Antimicrob. Chemother: (2000) 46:283–285.
   Google Scholar
• IWAO E, YOKOYAMA Y, YAMAMOTO K, HIRAYAMA F, HAGA K: In vitro and in vivo anti-Helicobacter pylori activity of Y-904, a new fluoroquinolone. Infect. Chemother: (2003) 9:165–171.
   Google Scholar
• GAJJAR DA, BELLO A, GE Z, CHRISTOPHER L, GRASELA DM: Multiple-dose safety and pharmacokinetics of oral garenoxacin in healthy subjects. Antimicrob. Agents Chemother. (2003) 47:2256–2263.
   PubMed Web of Science ®Google Scholar
• SHARARA Al, CHAAR HF, RACOUBIAN E et al.: Efficacy of two rabeprazole/gatifloxacin-based triple therapies for Helicobacter pylori infection. Helicobacter (2004) 9:255–261.
   PubMedGoogle Scholar
• DI CARO S, OJETTI V, ZOCCO MA et al.: Mono, dual and triple mwdfloxacin-based therapies for Helicobacter pylori eradication. Aliment. Pharmacol Then. (2002) 16:527–532.
   PubMed Web of Science ®Google Scholar
• SCARPIGNATO C, PELOSINI I: Antisecretory drugs for eradication of Helicobacterpy/ori: antibacterial activity and synergism with antimicrobial agents. Frog. Basic Clin. Pharmacol (1999) 11:136–180.
   Google Scholar
• ••This is an exhaustive review on protonpump inhibitors.
   Google Scholar
• GRAHAM DY, HAMMOUD F, EL-ZIMAITY MT et al.: Meta-analysis: proton pump inhibitor of H2-recptor antagonist for Helicobacter pylori eradication. Aliment. Pharmacol Then. (2003) 17:1229–1236.
   PubMed Web of Science ®Google Scholar
• KITA T, TANIGAWARA Y, AOYAM N et al.: CYP2C19 genotype related effect of omeprazole on intragrastric pH and antimicrobial stability. Pharm. Res. (2001) 18:615–621.
   PubMedGoogle Scholar
• FURUTA T, SHIRAI N, TAKASHIMA M et al.: Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxycillin, and clarithromycin. Clin. Pharmacol Then. (2001) 69:158–168.
   PubMed Web of Science ®Google Scholar
• GATTA L, PERNA F, FIGURA N et al:Antimicrobial activity of esomeprazole versus omeprazole against Helicobacter pylori. .1. Antimicrob. Chemother: (2003) 51:439–442.
   Google Scholar
• KIM JI, PARK SH, KIM JK et al: The effects of nocturnal acid breacktrhrough on Helicobacter pylori eradication. Helicobacter (2002) 7:331–336.
   PubMed Web of Science ®Google Scholar
• GALMICHE JP, BLEY DES SV, DUCROTTE P et al.: Tenatoprazole, a novel proton pump inhibitor with a prolonged plasma half-life: effects on intragastric pH and comparison with esomeprazole in healthy volunteers. Aliment. Pharmacol Then. (2004) 19:655–662.
   PubMed Web of Science ®Google Scholar
• ADACHI K, ISHIHARA S, HASHIMOTO T et al: Efficacy of sucralfate for Helicobacter pylori eradication triple therapy in comparison with a lansoprazole-based regimen. Aliment. Pharmacol Ther: (2000) 14:919–922.
   PubMed Web of Science ®Google Scholar
• VCEV A, VCEVA A, KURBEL S et al: Amoxycillin, clarithromycin and either sucralfate or pantoprazole for eradication of Helicobacter pylori in duodenal ulcer (a randomized controlled trial). Wien. Kiln. Wochenschr. (2001) 113:939–941.
   PubMedGoogle Scholar
• WU CJ, HSU PI, LO GH et al: Comparison of cetraxate-based and pantoprazole-based triple therapies in the treatment of Helicobacter pylori infection. J. Chin. Med. Assoc. (2004) 67:161–167.
   PubMedGoogle Scholar
• KATO M, ASAKA M, SUGIYAMA T et al.: Effects of rebamipide in combination with lansoprazole and amoxicillin on Helicobacter pylori-infected gastric ulcer patients. Dig. Dis. Sci. (1998) 43:198–202.
   Google Scholar
• OWEN RJ: Bacteriology of Helicobacter pylon. In: Helicobater pylori Calam J (Ed.) Baililèrec Clin. Castroenterol (1995) 9:415–446.
   Google Scholar
• ZULLO A, RINALDI V, HASSAN C et al.:H pylori and plasma ammonia levels in cirrhotics: role of urease inhibition by acetohydroxamic acid. Ital. J Castroenterol Hepatol (1998) 30:405–408.
   PubMedGoogle Scholar
• POPE AJ, TOSELAND CD, RUSHANT B, RICHARDSON S, MCVEY M, HILLS J: Effect of potent urease inhibitor, fluorofamide, on Helicobacter sp. M vivo and M vitro. Dig. Dis. Sci. (1998) 43:109–119.
   PubMed Web of Science ®Google Scholar
• SUZUKI H, NOMURA S, MASAOKA T et al.: Effect of dietary anti-Helicobacter pylori-urease immunoglobulin Y on Helicobacter pylori infection. Aliment. Pharmacol Ther: (2004) 20\(Supp1.1):185–192.
   Google Scholar
• GOTOH A, AKAMATSU T, SHIMIZU T et al.: Additive effect of pronase on the efficacy of eradication therapy against Helicobacter pylori Helicobacter (2002) 7:183–191.
   Google Scholar
• HAMILTON-MILLER JM: The role of probiotics in the treatment and prevention of Helicobacter pylori infection. Int. .1. Antimicrob. Agents (2002) 22:360–366.
   Google Scholar
• ••This is a systematic review on the role ofprobiotics in H pylori treatment.
   Google Scholar
• CANDUCCI F, ARMUZZI A, CREMONINI F et al.: A lyophilized and inactivated culture of Lactobacillus acidophils increases Helicobacter pylori eradication rate. Ailment. Pharmacol Then. (2000) 14:1625–1629.
   PubMed Web of Science ®Google Scholar
• SHEU BS, WU JJ, LO CY et al:Impact of supplement with Lactobacillus- and Bifidobacterium-containing yogurt on triple therapy for Helicobater pylori eradication. Aliment. Pharmacol Then. (2002) 16:1669–1675.
   PubMed Web of Science ®Google Scholar
• DE FRANCESCO V, STOPPINO V, SGARRO C et al.: Lactobacillus acidophilus administation added to omeprazole/ amoxicillin-based double therapy in Helicobacter pylori eradication. Dig. Liver Dis. (2000) 32:746–747.
   PubMedGoogle Scholar
• ARMUZZI A, CREMONINI F, BARTOLOZZI F et al.: The effect of oral administration of Lactobacillus CC on antibiotic-associated gastrointestinal side-effects during Helicobacter pylori eradication therapy. Ailment. Pharmacol Then. (2001) 15:163–169.
   PubMed Web of Science ®Google Scholar
• FELLEY CP, CORTHESY-THEULAZ I, RIVERO JLB et al.: Favourable effect on an acidified milk (LC-1) on Helicobacter pylori gastritis in man. Eur: Castroenterol Hepatol (2001) 13:25–29.
   PubMed Web of Science ®Google Scholar
• ARMUZZI A, CREMONINI F, OJETTI V et al.: Effect of Lactobacillus CC supplementation on antibiotic-associated gastrointestinal side effects during Helkobacter pylon eradication therapy: a pilot study. Digestion (2001) 63:1–7.
   PubMed Web of Science ®Google Scholar
• CREMONINI F, DI CARO S, COVINO M et al.: Effect of different probiotic preparations on anti-He/kobacterpy/oritherapy-related side effectes: a parallel group, triple blind, placebo-controlled study. Am.' Castroenterol (2002) 97:2744–2749.
   PubMed Web of Science ®Google Scholar
• USHIYAMA A, TNAKA K, AIBA Yet al.: Lactobacillus gasseriOLL2716 as a probiotic in clarithromycin-resistant Helicobacter py/oriinfection. Castroenterol Hepatol (2003) 18:986–991.
   Google Scholar
• MAHADY GB, PENDLAND SL, YUN GS, LU ZZ, STOIA A: Ginger (Zingiber officinak Rocco) and the gingerols inhibit the growth of CagA± strains of Helkobater pylori. Anti-Cancer Res. (2003) 23:3699–3702.
   PubMed Web of Science ®Google Scholar
• BHAMARAPRAVATI S, PENDLAND SL, MAHADY GB: Extract of spice and food plants from Thai traditional medicine inhibit the growth of the human carcinogen He/kobacterpy/ori In Vivo (2003) 17:541–544.
   Google Scholar
• YANAGAWA Y, YAMAMOTO Y, HARAY, SHIMAMURA T: A combination effect of epigallocatechin gallate, a major compound of green tea catechins, with antibiotics on Helicobacter pylori growth M vitro. Cum Microbial. (2003) 47:244–249.
   PubMed Web of Science ®Google Scholar
• NARIMAN F, EFTEKHAR F, HABIBI Z, FALSAFI T: Anti- Helicobacter pylori activities of six Iranian plants. Helicobacter (2004) 9:146–151.
   PubMed Web of Science ®Google Scholar
• OHNO T, KITA M, YAMAOKA Y et al: Antimicrobial activity of essential oils against Helicobacterpylori. Helicobacter (2003) 8:207–215.
   PubMed Web of Science ®Google Scholar
• CANIZARES P, GRACIA I, GOMEZ LA et al.: Allyl-thiosulfinates, the bacteriostatic compounds of garlic against Helicobacter pylori Biotechnol Frog. (2004) 20:397–401.
   Google Scholar
• MCNULTY CA WILSON MP, HAVINGA W et al: A pilot study to determine effectiveness of garlic oil capsules in the treatment of dyspeptic patients with Helicobacterpylori. Helicobacter (2001) 6:249–253.
   PubMedGoogle Scholar
• MARTIN KW, ERNST E. Herbal medicines for treatment of bacterial infections: a review of controlled clinical trials. Antimicrob. Chemother. (2003) 51:241–246.
   Google Scholar
• FAHEY JVV, HARISTOY X, DOLAN PM et al.: Sulforaphane inhibits extracellular, intracellular, and antibiotic-resistant strains of Helicobacter pylori and prevents benzoralpyrene-induced stomach tumors. Proc. Natl. Acad. Sci. USA (2002) 99:7610–7615.
   PubMedGoogle Scholar
• CASELLI M, PARENTE F, PALLID et al: `Cervia Working Group Report': guidelines on the diagnosis and treatment of Helicobacter pylori infection. Dig. Liver Dis. (2001) 33:75–80.
   PubMedGoogle Scholar
• CZINN SJ, NEDRUD JG: Oral immunisation against Helicobacter pylori Infect. Litman. (1991) 59:2359–2363.
   Google Scholar
• ••First demonstration of a vaccine withprotective effect against H pylori infection.
   Google Scholar
• DOIDGE C, GUST I, LEE A, BUCK F, HAZEL S, MANNE U: Therapeutic immunisation against Helicobacter pylori infection. Lancet (1994) 343:914–915.
   PubMed Web of Science ®Google Scholar
• ••First demonstration of a vaccine withtherapeutic effect in H pylori-infected mice.
   Google Scholar
• CHEN M, CHEN J, LIAO W et al.: Immunization with attenuated Salmonella hphimurium producing catalase in protection against Helicobacter pyloriinfection in mice. Helicobacter (2003) 8:613–625.
   PubMed Web of Science ®Google Scholar
• GOTTWEIN JM, BLANCHARD TG, TARGONI OS et al: Protective anti-Helkobacterimmunity is induced with aluminium hydroxide or complete Freund's adjuvant by systemic immunization. I Infect. Dis. (2001) 184:308–314.
   PubMed Web of Science ®Google Scholar
• JIANG W, BAKER HJ, SMITH BF: Mucosal immunization with Helkobactec CpG DNA, and cholera toxin is protective. Infect. Inman. (2003) 71:40–46.
   PubMed Web of Science ®Google Scholar
• KREISS C, BUCLIN T, COSMA M, CORTHESY THULAZ I, MICHETTI P: Safety of oral immunisation with recombinant urease in patients with Helicobacter pylori infection. Lancet (1996) 347:1630–1631.
   PubMed Web of Science ®Google Scholar
• MICHETTI P, KREISS C, KOTLOFF KL et al.: Oral immunization with urease and Escherichia coilheat-labile enterotoxin is safe and immunogenic in HeliwbaterpylorP infected adults. Gastroenterology (1999) 116:804–812.
   PubMed Web of Science ®Google Scholar
• BANERJEE S, MEDINA-FATIMI A, NICOLS R et al.: Oral immunization against H pyloriin healthy volunteers with low dose E colienterotoxin (LT) and recombinant urease. Cut (2000) 47\(Supp1.1):A59.
   Google Scholar
• KOTOLOFF KL, SZTEIN MB, WASSERMAN SS, DI LORENZO SC, WALKER RI: Safety and immunogenicity of oral inactivated whole-cell Helicobacter pylori vaccine with adjuvant among volunteers with or without subclinical infection. Infect. Inman. (2001) 69:3581–3590.
   PubMedGoogle Scholar
• DI PETRILLO MD, TIBBETTS T, KLEANTHOUS H, KILLEEN KP, HOHMANN EL: Safety and immunogenicity of phoP/phQ-deleted Salmonella typhi expressing Helicobacter pylori urease in adult volunteers. Vaccine (1999) 18:449–459.
   PubMedGoogle Scholar
• ANGELAKOPOULOS H, HOHMANN EL: Pilot study of phoP/p17Q-deleted Salmonella enterica serovar Typhimurium expressing Helicobacter pylori urease in adult volunteers. Infect. Immun. (2001) 69:3581–3590.
   PubMedGoogle Scholar
• BUMAN D, METZGER WG, MANSOURI E et al.: Safety and immunogenicity of live recombinant Salmonella enterica serovar Typhi Ty2 1 a expressing urease A and B from Helicobacter pylor i in human volunteers. Vaccine (2001) 20:845–852.
   PubMedGoogle Scholar
• METZGER WG, MANSOURI E, KRONAWITTER M et al.: Impact of vector-priming on the immunogenicity of a live recombinant Salmonella enterica serovar Typhi Ty2la vaccine expressing urease A and B from Helicobacter pylori in human volunteers. Vaccine (2004) 22:2273–2277.
   PubMed Web of Science ®Google Scholar
• BANATVALA N, FELDMAN R: The epidemiology of Helkobacter pylori: missing pieces in a jigsaw. Comm. Dis. Rep. Rev (1993) 3:56–59.
   Google Scholar